Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Robatumumab (Synonyms: School 717454, Sch717454, Sch 717454, MK-7454, MK7454, 19D12)

Catalog No. T76759 Copy Product Info
🥰Excellent
Robatumumab (Sch 717454) is a fully human anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody with antitumor and antiproliferative activity.Robatumumab is used in the study of ovarian cancer.

Robatumumab

Copy Product Info
🥰Excellent
Catalog No. T76759
Synonyms School 717454, Sch717454, Sch 717454, MK-7454, MK7454, 19D12

Robatumumab (Sch 717454) is a fully human anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody with antitumor and antiproliferative activity.Robatumumab is used in the study of ovarian cancer.

Robatumumab
Cas No. 934235-44-6
TargetMol | Customer service
Customer service consultation
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$189In StockIn Stock
5 mg$479In StockIn Stock
10 mg$768-In Stock
25 mg$1,150-In Stock
50 mg$1,550-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:96.9% (SDS-PAGE); 98.1% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Robatumumab (Sch 717454) is a fully human anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody with antitumor and antiproliferative activity.Robatumumab is used in the study of ovarian cancer.
In vitro
Robatumumab (0.02-80 nM; 0.5 or 4 hours) inhibited basal and IGF-I-induced phosphorylation of IGF-IR and IRS-1 in SK-N-FI cells by decreasing IGF-IR expression levels. [2]
In vivo
Robatumumab (i.v.; 0.04 or 0.1 mg/mouse; twice weekly; 18 days total) reduced SK-N-FI tumor growth in a xenograft model. [2]
Robatumumab (i.v.; 0.02-0.5 mg/mouse; twice weekly; 35 days) was effective in inhibiting osteosarcoma expansion in a xenograft model. [2]
Robatumumab (i.v.; 0.1 or 0.5 mg/mouse; twice weekly; 14 days) significantly inhibited the proliferation of SJCRH30 and RD rhabdomyosarcoma cells in a xenograft model. [2]
Robatumumab (intravenous; 0.1 or 0.5 mg/mouse; twice weekly; 2 weeks) effectively blocked the growth of pediatric tumor cells in vivo. [2]
Robatumumab (i.v.; 0.5 mg/mouse; single dose; day 11 post-vaccination) regulates blood vessel formation by exerting anti-angiogenic effects. [2]
SynonymsSchool 717454, Sch717454, Sch 717454, MK-7454, MK7454, 19D12
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetIGF1-R/IGFR1/CD221
Chemical Properties
Molecular Weight145.56 kDa
Cas No.934235-44-6
Antibody Information
IsotypeIgG1
Storage & Solubility Information
Storage-20°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Robatumumab | purchase Robatumumab | Robatumumab cost | order Robatumumab | Robatumumab in vivo | Robatumumab in vitro | Robatumumab molecular weight